BPG is committed to discovery and dissemination of knowledge
Articles in Press
10/30/2024 2:06:38 PM | Browse: 72 | Download: 31
Publication Name World Journal of Gastroenterology
Manuscript ID 101463
Country China
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients
Manuscript Source Unsolicited Manuscript
All Author List Wen Gao, Jing-Wen Li, Hui Ye, Xue-Zhi Zhang, Jian-Xiang Liu and Hong Cheng
Funding Agency and Grant Number
Funding Agency Grant Number
National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital) 2023YC27
Capital’s Funds for Health Improvement and Research 2022-2-40711
National High Level Hospital Clinical Research Funding (Interdepartmental Research Project of Peking University First Hospital) 2024IR20
Corresponding Author Hong Cheng, MD, Professor, Department of Gastroenterology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. chenghong1969@163.com
Key Words Helicobacter pylori; Vonoprazan; Amoxicillin; Dual therapy; Elderly
Core Tip Vonoprazan-amoxicillin (VA) dual treatment is as effective as traditional bismuth-based quadruple therapy for the eradication of Helicobacter pylori (H. pylori) in the general population. However, the safety of this regimen in the elderly population is unknown. This real-world study retrospectively analyzed data from elderly patients treated for H. pylori infection. VA dual therapy demonstrated good safety and efficacy in the elderly patients with an eradication rate similar to that of the general population. The findings provided evidence supporting the use of VA dual therapy in elderly patients.
Citation Gao W, Li JW, Ye H, Zhang XZ, Liu JX, Cheng H. Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients. World J Gastroenterol 2024; In press
Received
2024-09-15 14:14
Peer-Review Started
2024-09-15 14:14
To Make the First Decision
Return for Revision
2024-09-27 19:29
Revised
2024-10-07 15:28
Second Decision
2024-10-30 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2024-10-30 14:06
Articles in Press
2024-10-30 14:06
Publication Fee Transferred
2024-10-30 14:29
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com